Risk calculators improve OH management
September 1st 2007Several risk calculators are available to help assess the likelihood that a patient with ocular hypertension will develop glaucoma. The decision to treat then can be based on an individual patient's risk. That determination may be guided by expert opinion, results of decision analysis models, personal experience, and discussion with the patient.
Study explores mechanism of increased nocturnal IOP
September 1st 2007A study of the mechanisms involved in nocturnal changes in IOP indicates that a decrease in outflow facility is insufficient to compensate for a decrease in aqueous outflow. Episcleral venous pressure could be a factor in the circadian variations, however.
Prognosis not always bleak for young Chinese patients with OAG diagnosis
September 1st 2007Progressive myopia rather than glaucoma may be primarily responsible for glaucomatous-appearing optic nerve damage in a subset of young to middle-aged individuals of Chinese descent. In a retrospective study of 16 Chinese men who were glaucoma suspects or patients, visual fields remained stable over a follow-up period of up to 7 years, leading researchers to postulate that this condition may not have the same natural history as primary open angle glaucoma in other populations. A correlation between myopia and glaucomatous optic nerve damage has long been known, and has recently been confirmed in several populations, including China.
Patient selection, technique critical to phakic IOL success
September 1st 2007Phakic IOLs can provide accurate and stable correction of myopia, but their potential to result in serious complications remains a cause for concern. Care in selecting appropriate candidates and the implantation procedure are critical to optimize the risk:benefit ratio.
'Soft' corticosteroids, cyclosporine recommended for dry eye
August 15th 2007Research has shown that dry eye syndrome is largely due to inflammation. Therefore, "soft" corticosteroids such as loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch & Lomb) or fluorometholone ophthalmic suspension 0.1% (FML, Allergan), or cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), may be effective.
Dry eye common a chronic, debilitating disorder
August 15th 2007Dry eye is estimated to affect 25% of those who visit a general ophthalmology clinic. The disorder has a significant effect on quality of life. In this article, one ophthalmologist reviews how to evaluate patients presenting with dry eye complaints and how to manage the condition.
Practitioners see eye-to-eye when diagnosing, treating dry eye
August 15th 2007Optometrists, general ophthalmologists, and cornea subspecialists have similar approaches to diagnosing and treating dry eye. Three clinician groups that relied on fluorescein staining and TFBUT for diagnosis found that cyclosporine emulsion 0.05% (Restasis, Allergan) was an important component of treatment for the majority of their eye-care practitioners.
Topical cyclosporine treatment enhances outcomes of multifocal IOL implantation
August 15th 2007A prospective, randomized, contralateral eye controlled study found that visual acuity and contrast sensitivity outcomes in patients undergoing bilateral cataract surgery with implantation of a multifocal IOL were improved by treatment pre- and postoperatively with topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan).
Prospective study finds favorable dry eye profile after SBK
August 15th 2007A prospective study of 50 patients undergoing bilateral laser-vision correction surgery randomly assigned one eye to PRK and the fellow eye to femtosecond thin-flap (110 µm) sub-Bowman's keratomileusis (SBK). The results show that during 6 months of follow-up, dry eye signs and symptoms are generally similar with the thin flap and surface ablation procedures.
'Soft' corticosteroids, cyclosporine recommended for dry eye
August 15th 2007Research has shown that dry eye syndrome is largely due to inflammation. Therefore, "soft" corticosteroids such as loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch & Lomb) or fluorometholone ophthalmic suspension 0.1% (FML, Allergan), or cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan), may be effective.
One dry eye drop found superior to saline in study
August 15th 2007The tissue-on-tissue model, rather than tests using plastic or metal surfaces, is the best way to test the lubricity of ophthalmologic formulations, according to a new study. Using this model, a particular dry eye drop was found to be statistically significantly superior to saline.
Treatment trial examines visual effects of continuous artificial tear use
August 15th 2007A study examining the effect of artificial tear instillation on contrast sensitivity found that, in patients with dry eye a temporary loss with initial use disappears as the treatment is continued. Further investigations are evaluating if the finding reflects a benefit on the tear layer.
Olopatadine 0.2% safe, effective, well tolerated in study
August 15th 2007Olopatadine HCl 0.2% ophthalmic solution (Pataday, Alcon Laboratories) is safe, effective, and well-tolerated when applied once daily to treat the ocular signs and symptoms of allergic conjunctivitis or rhinoconjunctivitis. In addition, the activity of olopatadine 0.2% was found to be superior to that of epinastine HCl 0.05% (Elestat, Inspire Pharmaceuticals and Allergan) in alleviating ocular itching and redness induced by conjunctival allergen challenge.
Epinastine ophthalmic solution earns high marks for comfort, tolerability in comparison study
August 15th 2007Adult patients with a history of allergic conjunctivitis gave epinastine (Elestat, Inspire Pharmaceuticals and Allergan) high marks for tolerability and comfort in a recent single-center, double-masked, four-visit crossover study.
Allergy season can be hardest on the eyes
August 15th 2007Ocular symptoms of allergies for many are as severe as rhinitis symptoms said Stephen C. Pflugfelder, MD. Ocular manifestations of seasonal allergies include seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC), said Dr. Pflugfelder. The ideal therapy should include multiple steps in the allergy cascade, perhaps by neutralizing both the H1 and H2 receptors, stabilizing the mast cells, and having anti-inflammatory properties.
Ketotifen fumarate safe, effective against ocular allergies, says one clinician
August 15th 2007A proprietary formulation of ketotifen fumarate ophthalmic solution 0.025% (Alaway, Bausch &Lomb) offers a highly safe and effective treatment for allergic conjunctivitis with the convenience benefits of an OTC medication.
Could yogurt solve allergy problems?
August 15th 2007The hygiene hypothesis suggests that smaller family sizes as well as the use of antibiotics and vaccines has led to an allergy epidemic. Probiotics could reverse that epidemic and reduce the risk of developing atopic diseases and, potentially, nasal and ocular symptoms of respiratory allergies.
Lubricating eye drops mimic composition of human tears
August 15th 2007Sodium carboxymethylcellulose (CMC) 0.25% lubricating eye drops (TheraTears, Advanced Vision Research) mimic the composition of the human tear film and promotes healing of irritation of the ocular surface caused by dry eye, according to the recently released final report of the Dry Eye Workshop.
Develop the future of your practice
August 15th 2007An ophthalmologist can give a great eye exam, but to be successful in a family practice the eye-care professional (ECP) must make sure the child-patient feels cheerful, healthy, and participative. The environment should welcome young patients. Their positive attitudes will reflect on a staff.